2021
Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas
Eder JP, Doroshow DB, T. K, Keedy VL, Sklar JS, Glazer P, Bindra R, Shapiro GI. Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas. JCO Precision Oncology 2021, 5: 466-472. PMID: 34994649, PMCID: PMC9848565, DOI: 10.1200/po.20.00247.Peer-Reviewed Original ResearchConceptsPulmonary epithelioid hemangioendotheliomaStable diseaseEpithelioid hemangioendotheliomaClinical benefitClinical benefit rateOpen-label studyPrimary end pointPoly (ADP-ribose) polymerase inhibitionDefective homologous recombination (HR) repairMesenchymal sarcomaObjective responsePartial responseClinical efficacyPatient populationBenefit rateCombination trialsPatientsSolid tumorsIDH1/2-mutant tumorsIDH1/2 mutationsPARP inhibitorsEnd pointPARP inhibitionTumorsOlaparib
1999
BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations.
Turner B, Harrold E, Matloff E, Smith T, Gumbs A, Beinfield M, Ward B, Skolnick M, Glazer P, Thomas A, Haffty B. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. Journal Of Clinical Oncology 1999, 17: 3017-24. PMID: 10506595, DOI: 10.1200/jco.1999.17.10.3017.Peer-Reviewed Original ResearchConceptsBreast cancer patientsDeleterious BRCA1/2 mutationsCancer patientsBRCA1/2 mutationsControl patientsAge 40BRCA2 mutationsRadiation therapyControl breast cancer patientsNew primary breast cancerRecurrent breast cancer patientsEarly-onset breast cancer patientsBRCA1/BRCA2 mutationsBreast-conserving managementBreast-conserving therapySecond primary tumorsPrimary breast cancerOutcome of treatmentBRCA2 germline mutationsBRCA1/BRCA2 germline mutationsSalvage mastectomySystemic progressionLocal relapseMedian timeRecurrent cancer